This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	Protein kinase C (PKC)	<i>In vitro</i> studies suggest a new class of PKC agonists could help treat HIV infection. Chemical synthesis and <i>in vitro</i> testing of bryostatin analogs identified seven compounds as low nanomolar PKC agonists. In a human T cell line model of latent HIV infection, the compounds reactivated latent virus at nanomolar and subnanomolar EC ₅₀ values, which would render the virus sensitive to standard antiretroviral drugs. A forthcoming publication will report the results of testing the compounds in blood samples from patients with HIV who are on antiretroviral therapy and have undetectable serum levels of the virus.	Patented; available for licensing	DeChristopher, B.A. <i>et al. Nat. Chem.</i> ; published online July 15, 2012; doi:10.1038/nchem.1395 Contact: Paul A. Wender, Stanford University, Stanford, Calif. e-mail: wenderp@stanford.edu Contact: Jerome A. Zack, University of California, Los Angeles, Calif. e-mail: jzack@ucla.edu
SciBX 5(29); doi:10.1038/scibx.2012.759 Published online July 26, 2012				